Business · 25/06/1997

FDA Revises Postmarketing Adverse Experience Reporting Regulations

The FDA is eliminating the requirement for increased frequency reports for human drug and licensed biological products, aiming to streamline postmarketing reporting of adverse experiences and align with the President's regulatory reinvention initiative.